Apontis Pharma Past Earnings Performance
Past criteria checks 0/6
Apontis Pharma's earnings have been declining at an average annual rate of -32%, while the Pharmaceuticals industry saw earnings growing at 10.5% annually. Revenues have been growing at an average rate of 8.3% per year.
Key information
-32.0%
Earnings growth rate
-58.3%
EPS growth rate
| Pharmaceuticals Industry Growth | 7.3% |
| Revenue growth rate | 8.3% |
| Return on equity | -37.3% |
| Net Margin | -30.6% |
| Next Earnings Update | 08 May 2024 |
Recent past performance updates
Recent updates
Potential Upside For Apontis Pharma AG (ETR:APPH) Not Without Risk
Apr 05
We Think Apontis Pharma (ETR:APPH) Can Afford To Drive Business Growth
Dec 02Not Many Are Piling Into Apontis Pharma AG (ETR:APPH) Stock Yet As It Plummets 27%
Jul 29Apontis Pharma's (ETR:APPH) Robust Earnings Are Supported By Other Strong Factors
Apr 08Revenue & Expenses BreakdownBeta
How Apontis Pharma makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 37 | -11 | 21 | 0 |
| 30 Sep 23 | 42 | -7 | 21 | 0 |
| 30 Jun 23 | 46 | -3 | 20 | 0 |
| 31 Mar 23 | 51 | 0 | 20 | 0 |
| 31 Dec 22 | 56 | 3 | 20 | 0 |
| 30 Sep 22 | 56 | 3 | 19 | 0 |
| 30 Jun 22 | 56 | 4 | 17 | 0 |
| 31 Mar 22 | 54 | 2 | 18 | 0 |
| 31 Dec 21 | 51 | -1 | 20 | 0 |
| 30 Sep 21 | 48 | -1 | 21 | 0 |
| 30 Jun 21 | 46 | -1 | 22 | 0 |
| 31 Mar 21 | 42 | -1 | 20 | 0 |
| 31 Dec 20 | 39 | -1 | 18 | 0 |
| 31 Dec 19 | 40 | -2 | 19 | 0 |
| 31 Dec 18 | 20 | 0 | 8 | 0 |
Quality Earnings: APPH is currently unprofitable.
Growing Profit Margin: APPH is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: APPH is unprofitable, and losses have increased over the past 5 years at a rate of 32% per year.
Accelerating Growth: Unable to compare APPH's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: APPH is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (2.7%).
Return on Equity
High ROE: APPH has a negative Return on Equity (-37.35%), as it is currently unprofitable.